View All Cancer Clinical Trials | The University of Kansas Cancer Center

Viewed View Trial

A Randomized Phase II Trial of Cabozantinib and Cabozantinib Plus Nivolumab Versus Standard Chemotherapy in Patients with Previously Treated NonSquamous NSCLC

Study Type: Treatment

Phase: II

NCTID: NCT04310007

Principal Investigator: Gary Doolittle

Viewed View Trial

A Phase 1 Study of SEA-CD70 in Myeloid Malignancies

Study Type: Treatment

Phase: I

NCTID: NCT04227847

Principal Investigator: Abdulraheem Yacoub

Viewed View Trial

A Randomized Phase II Study of Erdafitinib Versus Investigator Choice of Intravesicular Chemotherapy in Subjects Who Received Bacillus Calmette-Gu�rin BCG and Progressed or Recurred With High Risk Non-Muscle-Invasive Bladder Cancer NMIBC and FGFR Mutations or Fusions

Study Type: Treatment

Phase: II

NCTID: NCT04172675

Principal Investigator: Eugene Lee

Viewed View Trial

A Phase I Study of ZEN003694 ZEN3694 in Combination with Cetuximab and Encorafenib in Patients with Refractory BRAF V600E Metastatic Colorectal Cancer

Study Type: Treatment

Phase: I

NCTID: NCT06102902

Principal Investigator: Haoran Li

Viewed View Trial

Phase I/II Study of Dabrafenib, Trametinib, and Navitoclax in BRAF Mutant Melanoma Phase I and II and Other Solid Tumors Phase I Only.

Study Type: Treatment

Phase: I/II

NCTID: NCT01989585

Principal Investigator: Gary Doolittle

Viewed View Trial

Birinapant and Intensity Modulated Re-Irradiation Therapy IMRRT for Locoregionally Recurrent Head and Neck Squamous Cell Carcinoma HNSCC

Study Type: Treatment

Phase: I

NCTID: NCT03803774

Principal Investigator: Prakash Neupane

Viewed View Trial

A Phase III Randomized, Double-Blind, Placebo-Controlled, Multi- Regional, International Study of Durvalumab in Combination with Gemcitabine plus Cisplatin versus Placebo in Combination with Gemcitabine plus Cisplatin for Patients with First-Line Advanced Biliary Tract Cancers TOPAZ-1

Study Type: Treatment

Phase: III

NCTID: NCT03875235

Principal Investigator: Weijing Sun

Viewed View Trial

A Phase IB, Open-Label, Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of UTTR1147A in Combination with Standard of Care in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Study Type: Prevention

Phase: I

NCTID: NCT04539470

Principal Investigator: Sunil Abhyankar

Viewed View Trial

Open-Label, Multicenter, Phase I Study to Assess the Safety of P-BCMA-ALLO1 in Subjects with Relapsed / Refractory Multiple Myeloma MM

Study Type: Treatment

Phase: I

NCTID: NCT04960579

Principal Investigator: Leyla Shune

Viewed View Trial

A Phase III Randomized, Open-Label Study of Optune Ttfields, 200KHZ Concomitant with Radiation Therapy and Temozolomide for the Treatment of Newly Diagnosed Glioblastoma

Study Type: Treatment

Phase: III

NCTID: NCT04471844

Principal Investigator: Shalina Gupta-Burt

Find a Clinical Trial

A Randomized Phase II Trial of Cabozantinib and Cabozantinib Plus Nivolumab Versus Standard Chemotherapy in Patients with Previously Treated NonSquamous NSCLC

A Phase 1 Study of SEA-CD70 in Myeloid Malignancies

A Randomized Phase II Study of Erdafitinib Versus Investigator Choice of Intravesicular Chemotherapy in Subjects Who Received Bacillus Calmette-Gu�rin BCG and Progressed or Recurred With High Risk Non-Muscle-Invasive Bladder Cancer NMIBC and FGFR Mutations or Fusions

A Phase I Study of ZEN003694 ZEN3694 in Combination with Cetuximab and Encorafenib in Patients with Refractory BRAF V600E Metastatic Colorectal Cancer

Phase I/II Study of Dabrafenib, Trametinib, and Navitoclax in BRAF Mutant Melanoma Phase I and II and Other Solid Tumors Phase I Only.

Birinapant and Intensity Modulated Re-Irradiation Therapy IMRRT for Locoregionally Recurrent Head and Neck Squamous Cell Carcinoma HNSCC

A Phase III Randomized, Double-Blind, Placebo-Controlled, Multi- Regional, International Study of Durvalumab in Combination with Gemcitabine plus Cisplatin versus Placebo in Combination with Gemcitabine plus Cisplatin for Patients with First-Line Advanced Biliary Tract Cancers TOPAZ-1

A Phase IB, Open-Label, Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of UTTR1147A in Combination with Standard of Care in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Open-Label, Multicenter, Phase I Study to Assess the Safety of P-BCMA-ALLO1 in Subjects with Relapsed / Refractory Multiple Myeloma MM

A Phase III Randomized, Open-Label Study of Optune Ttfields, 200KHZ Concomitant with Radiation Therapy and Temozolomide for the Treatment of Newly Diagnosed Glioblastoma

Popular Links